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Abstract 
Introduction: Diagnosing Fracture-Related Infections (FRI) based on clinical symptoms alone can be 
challenging and additional diagnostic tools such as serum inflammatory markers are often utilized. The aims of 
this study were 1) to determine the individual diagnostic performance of three commonly used serum 
inflammatory markers: C-Reactive Protein (CRP), Leukocyte Count (LC) and Erythrocyte Sedimentation Rate 
(ESR), and 2) to determine the diagnostic performance of a combination of these markers, and the additional 
value of including clinical parameters predictive of FRI. 
Methods: This cohort study included patients who presented with a suspected FRI at two participating level I 
academic trauma centers between February 1st 2009 and December 31st 2017. The parameters CRP, LC and 
ESR, determined at diagnostic work-up of the suspected FRI, were retrieved from hospital records. The gold 
standard for diagnosing or ruling out FRI was defined as: positive microbiology results of surgically obtained 
tissue samples, or absence of FRI at a clinical follow-up of at least six months. The diagnostic accuracy of the 
individual serum inflammatory markers was assessed. Analyses were done with both dichotomized values using 
hospital thresholds as well as with continuous values. Multivariable logistic regression analyses were performed 
to obtain the discriminative performance (Area Under the Receiver Operating Characteristic, AUROC) of (1) 
the combined inflammatory markers, and (2) the added value of these markers to clinical parameters.  
Results: A total of 168 patients met the inclusion criteria and were included for analysis. CRP had a 38% 
sensitivity, 34% specificity, 42% positive predictive value (PPV) and 78% negative predictive value (NPV). For LC 
this was 39%, 74%, 46% and 67% and for ESR 62%, 64%, 45% and 76% respectively. The diagnostic accuracy was 
52%, 61% and 80% respectively. The AUROC was 0.64 for CRP, 0.60 for LC and 0.58 for ESR. The AUROC of 
the combined inflammatory markers was 0.63. Serum inflammatory markers combined with clinical parameters 
resulted in AUROC of 0.66 as opposed to 0.62 for clinical parameters alone.  
Conclusion: The added value of CRP, LC and ESR for diagnosing FRI is limited. Clinicians should be cautious 
when interpreting the results of these tests in patients with suspected FRI. 
Key words: Fracture-Related Infections, Serum Inflammation Markers, White Blood Cell Count, Erythrocyte 
Sedimentation Rate, C-reactive Protein, Diagnostic accuracy, osteomyelitis, infection, fracture, trauma. 
Introduction 
Fracture-Related Infection (FRI) is a challenging 
complication after surgical fracture treatment (1, 2). 
Consequences include reoperations, prolonged 
treatment with antibiotics, prolonged immobilization, 
inability to participate in social and work-related 








even amputation.(3-5) As with most medical 
conditions, a successful treatment outcome starts with 
an accurate diagnosis. The fact that the clinical 
presentation of infection can be obscured by 
apparently normal wound healing is one of the 
difficulties of diagnosing FRI. When wound healing is 
compromised, and the classical infection symptoms 
such as pain, increased temperature, local erythema 
and swelling are present, FRI is usually easy to 
recognize. However, FRI can also present less 
apparent with symptoms mimicking those of delayed- 
or non-union, such as pain, implant failure and 
impaired fracture healing. It might even be present 
without any clinical signs and symptoms at all (1, 6, 
7). 
Another difficulty has been that until recently, 
the literature regarding the diagnosis and treatment of 
FRI was hampered by the lack of a clear definition (4). 
However, in 2017, the characteristics of a FRI were 
clearly defined in a consensus meeting between 
experts in the field of bone infection in collaboration 
with the Arbeitsgemeinschaft für Osteosynthese-
fragen (AO Foundation) and the European Bone and 
Joint Infection Society (EBJIS) (2). Two levels of 
certainty around diagnostic features were defined. 
Signs that are suggestive of FRI can be clinical signs of 
infection (such as redness, fever and new onset of joint 
effusion), radiological signs (for example bone lysis, 
sequestration, implant loosening, nonunion and 
periosteal bone formation), wound drainage and 
elevated serum inflammatory markers. Confirmatory 
clinical signs are a fistula, sinus, purulent drainage or 
wound breakdown which communicates to the bone 
itself or to the fixation device. In absence of these 
confirmatory clinical signs, the diagnosis can be 
confirmed by either microbiology (with 
phenotypically indistinguishable pathogens identified 
by culture from at least two separate deep 
tissue/implant specimens) or histology (presence of 
microorganisms in deep tissue taken during an 
operative intervention) (2). 
Elevated serum inflammatory markers are often 
used as diagnostic parameters for postoperative 
infections after orthopedic trauma surgery and are 
mainly investigated in PJIs (8, 9). Although they are 
considered to be indicative for the presence of FRI 
according to the aforementioned consensus meeting, 
research focusing on the added value of these 
parameters for diagnosing FRI is limited (10-13). In a 
recent survey amongst medical specialists involved in 
the care for patients with FRI, C-reactive protein 
(CRP) was regarded to be the most valuable tool for 
diagnosing FRI, followed by the Erythrocyte 
Sedimentation Rate (ESR) and Leucocyte Count (LC) 
respectively (14). However, the added value of serum 
inflammatory markers is still under debate. Large 
cohort studies which tell us whether these markers 
are capable of distinguishing a bacterial infection 
from a normal inflammatory response due to the 
injury, tissue damage, fracture healing, or the fracture 
surgery, are lacking so far (15-19). It is therefore 
mandatory to assess the role of these serum 
inflammatory markers in the decision-making process 
for diagnosing FRI. 
The two aims of the current study were: 
1) To determine the individual diagnostic 
performance of the three commonly used serum 
inflammatory markers, CRP, LC and ESR, in FRI. 
2) To assess the diagnostic value of a 
combination of these markers, and their value in 
addition to clinical parameters predictive of FRI. 
Patients and Methods 
Study design  
This is a retrospective cohort study performed at 
the University Medical Center Utrecht (UMCU) and 
the University Medical Center Groningen (UMCG), 
two Level I academic trauma centers in the 
Netherlands.  
In- and exclusion criteria 
In order to be able to calculate the accuracy of 
serum inflammatory markers in both patients with 
and without FRI, patients from a previous assembled 
database on medical imaging for suspected FRI were 
included. This database comprised of all patients who 
underwent nuclear medical imaging for suspected 
FRI between February 1st 2009 and December 31st 2017 
of the UMCU and UMCG. In accordance with clinical 
practice, where serum inflammatory markers are 
ordered when an infection is suspected, blood 
sampling had to be obtained within a range of seven 
days around the date an FRI was first considered 
(mostly at the outpatient department). Cases missing 
inflammatory markers or outcome data due to 
incomplete reporting were excluded from the 
analyses. In uncomplicated orthopedic- and 
traumatologic cases, levels of CRP peak at the second 
postoperative day. In uneventful cases, the CRP 
returns to normal values between day two to twelve 
postoperatively (20-25). Maximum values of LC are 
seen on day one to three postoperatively and decline 
to normal values between day four to six (26). Values 
of ESR peak at day seven to eleven postoperatively 
and decrease gradually until after week six (19). 
Therefore, patients were excluded who underwent 
surgery in 14 days preceding testing for CRP, 7 days 
for LC and 6 weeks for ESR testing. In- and exclusion 
criteria are presented in Table 1.  
 




Table 1. Inclusion and exclusion criteria. 
Inclusion Exclusion 
1. Patients with a suspected 
Fracture-Related Infection.  
1. Patients who underwent surgery in 
the fourteen days preceding collection of 
the blood sample for determining the 
serum inflammatory markers 
2. Pathologic fractures 
3. Prosthetic joint infection (PJI) 
4. Hematogenous infection 
5. Patients with (auto-)immune diseases 
6. Patients with (pre-)malignancies 
7. Concomitant use of corticosteroids 
8. Evident other focus of infection 
9. No reference standard available 




The study protocol was evaluated by the 
institutional review board (medical ethical research 
commission, METC) of the UMCU and found to be 
exempted from further approval requirements 
(METC-17-694). 
Serum Inflammatory Markers 
The index test comprised of CRP and LC. 
Analysis was done similarly in both participating 
centers. In the UMCU, blood was drawn into a 2.0 mL 
vacuum tube (BD Vacutainer; BD Medical Systems, 
Franklin Lakes, NJ, USA) containing K2-EDTA as an 
anticoagulant for blood cell analysis and a 4.0 mL 
vacuum tube Lithium-Heparin as an anticoagulant for 
CRP measurement. 
The UMCG used standard 4.0 mL K2 EDTA and 
4.5 mL Lithium-Heparin tubes. All blood samples 
were analyzed in the central diagnostic laboratories of 
the UMCU and UMCG (both with full ISO-15189 
accreditation). C-reactive protein (CRP) was 
measured using a turbidimetric immunoassay on a 
DxAU 5811 automated chemistry analyzer 
(Beckman-Coulter, Brea, CA, USA). Similar analysis 
was done in the UMCG using a Roche CRPL3 
analyzer with wide range assay (Roche, Mannheim, 
Germany). LC was measured using a Cell-Dyn 
Sapphire hematology analyzer (Abbott Diagnostics, 
Santa Clara, CA, USA). This analyzer uses 
spectrophotometry, electrical impedance and laser 
light scattering (multi angle polarized scatter 
separation, (MAPPS)) to classify blood cells (27, 28). In 
the UMCG, similar analysis was done using a Sysmex 
XN-20 Automated hematology analyzer (Sysmex, 
Kobe, Japan). The validity of all test results was 
checked with built-in quality flags, daily quality 
control samples and external quality assessment 
schemes. The ESR was measured using a method 
according to Westergren. The UMCU uses whole 
blood anticoagulated with sodium citrate 3,2% (4:1) in 
combination with a ESR analyzer (Monitor V100, Vital 
Diagnostics, SrL, Forli, Italy), in the UMCG the ESR 
was measured in EDTA whole blood in diluted with 
sodium citrate 3,2% (4:1) combination with the 
Starrsed interrliner (Mechatronics, Zwaag, the 
Netherlands) (29). 
Although analyses of blood samples were done 
in a similar set-up, both participating centers used 
slightly different threshold values for the serum 
makers. Since statistical calculations in this paper 
were performed on data from both centers to improve 
the possible predictive performance, common 
threshold values used in clinical practice and reported 
in medical literature were used to reflect the current 
performance of the separate parameters. The 
threshold in this study for CRP was less than 5.0 
mg/L and leukocyte count less than 10.0 x 109/L. For 
ESR, the threshold for men was 11 mm/h and for 
women 24 mm/h.  
Clinical parameters 
The clinical parameters included in the 
multivariate analysis were Gustilo-Anderson 
classification, ISS, diabetes mellitus, smoking status 
and lower extremity fractures. These parameters were 
used as these are known to increase the risk of a FRI 
(30).  
Reference standard 
The gold standard in the final diagnosis of FRI 
was based on the outcome of medical microbiology 
(MMB) results of at least two separate samples of 
deep tissue taken during a surgical intervention.(2) 
Two experienced trauma surgeons (GG and FIJ, >5 
years board certified) assessed the validity of the 
MMB results. Only if two or more deep samples were 
taken from the suspected area of bone infection, the 
MMB results were regarded as relevant. Only when 
two or more samples were positive with both 
morphologically the same organism, the MMB results 
were regarded as positive. In case of no surgery (and 
therefore no intra-operative cultures), the definite 
diagnosis was based on a clinical follow-up of at least 
six months. Throughout the follow-up, a final 
diagnosis was made on basis of positive clinical 
confirmatory criteria. When the aforementioned 
confirmatory signs were present perioperatively, the 
patient was also considered to be suffering from FRI 
(2).  
Data collection 
The electronic patient files of all included 
patients were scrutinized on when an infectious 
complication was first suspected and data was 
collected on demographics, type of fracture according 
to the Müller AO Classification of Fractures (31), 
Gustilo Anderson classification in case of an open 
fracture (32), date, trauma mechanism, fracture type 




and surgical management of the index trauma, 
laboratory findings, microbiology results, final 
diagnosis and clinical outcome during follow-up. 
Statistical analysis 
Continuous data are presented as mean and 
standard deviation (SD) in case of normal 
distributions or median and interquartile range (IQR) 
when not normally distributed. The baseline 
characteristics per center were compared to analyze 
whether there were any substantial differences 
between the centers. Hypothesis testing was done 
using independent t-test or Mann-Whitney U test for 
the continues values, and Chi-squared test or Fisher’s 
exact test for the dichotomized values. A p-value of 
<0.05 was considered significant.  
In the first analysis, the serum markers were 
dichotomized using the aforementioned threshold 
values, as this reflects the diagnostic performance in 
current clinical practice. For each parameter, true 
positive (TP), true negative (TN), false positive (FP) 
and false negative (FN) results were described. 
Contingency tables were constructed. Sensitivity and 
specificity, positive and negative predictive values 
(PPV and NPV), positive and negative likelihood 
ratio’s (LR+ and LR) were calculated. Second, to 
assess the maximal predictive performance, separate 
continuous values were used.  
Third, to assess the diagnostic performance of 
the combination of the inflammatory markers, a 
multivariable logistic regression model including the 
inflammatory markers was fitted. Subsequently, two 
models were fitted to determine the added value of 
the inflammatory markers to the clinical parameters. 
The first one included the clinically predetermined 
parameters. The second one included these 
parameters, and also the combined inflammatory 
markers. To reduce the risk of overfitting, a maximum 
of one predictor per 5-10 events was used.  
The diagnostic performance of these continuous 
models was assessed using the AUROC as a measure 
of discrimination. The Q-point method, which 
determines the threshold value closest to the upper 
left corner of the AUROC, was used to deduct the 
optimal threshold, for which the sensitivity and 
specificity were calculated.  
Sensitivity analyses were performed to (1) assess 
whether the diagnostic performance of the 
multivariable logistic regression analysis differs per 
center, (2) whether the time interval (<14 days versus 
≥14 days between inflammatory markers and 
intra-operative cultures) affects the diagnostic 
performance and (3) to assess whether the linearity 
assumption of the combined markers with the (logit) 
outcome affects the performance, through 
log-transforming the variables.  
All data analyses were performed using the 
Statistical Package for Social Sciences (SPSS®) 
statistics for Windows (version 20.0.0.0, IBM, 
Armonk, NY, USA). Where applicable, the reporting 
of this study followed the Transparent Reporting of a 
multivariable Prediction Model for individual 
diagnosis or prognosis (TRIPOD statement) (33). 
Results 
The cohort consisted of 365 patients who 
underwent medical imaging for suspected FRI. A total 
of 197 patients were excluded from analyses due to 
missing data on serum inflammatory markers (n=171) 
or other parameters. After exclusion, a total of 168 
patients were included in this study. Basic 
demographics and clinical characteristics of the 
included patients from both participating centers are 
shown in Table 2. The cohort consisted predominantly 
of male patients (n=115, 68.5%) with a median age of 
54 (IQR 40-62). Fractures were most commonly 
located in the lower extremity (n=140, 83.4%). The 
study population consisted of patients who were 
suspected to suffer from long standing FRI. The 
median interval between initial fracture surgery and 
nuclear imaging for a suspected FRI was 480 (IQR 
229-1312) days. 
FRI in study population 
Overall, FRI was present in 61 patients (36%). In 
the cohort, 41 patients were diagnosed with FRI on 
basis of MMB results. Twenty patients with negative 
or without MMB results developed FRI during the 
follow up. The median clinical follow up in the cohort 
was 53 (IQR 45-134) weeks. Median interval between 
blood sampling for laboratory analysis and 
operatively obtained samples for MMB was 49 (IQR 
19-85) days.  
Diagnostic performance of serum 
inflammatory markers 
Details on the serum markers are shown in Table 
3. For CRP, there were 49 TP, 36 TN, 69 FP and 10 FN 
results. This corresponds to 83% sensitivity and 34% 
specificity. When considering CRP as a continuous 
variable, an AUROC of 0.64 (0.55-0.72) was found. 
The optimum threshold was 10.5 mg/L, with a 
corresponding 61.0% sensitivity and 62.9% specificity. 
For leukocyte count, there were 22 TP, 72 TN, 26 FP 
and 35 FN results. This resulted in a 39% sensitivity 
and 74% specificity. When analyzed as a continuous 
variable the AUROC was 0.60 (0.50-0.69). The 
optimum threshold was 8.6 x109/L, with a 
corresponding 60.0% sensitivity and 61.2% specificity. 
Regarding ESR, there were 18 TP, 35 TN, 11 FP and 22 




FN results. This is consistent with 45% sensitivity and 
76% specificity. When analyzed as a continuous 
variable, the AUROC was 0.58 (0.46-0.71). At the 
optimum threshold (10.0), sensitivity was 72.4% 
specificity 50.1%. The results are presented in Table 4 
and Table 5. 
 
Table 2. Baseline characteristics of study population. 
 Both centers UMCU (n=41) UMCG (n=127) p-value 
Age (median (IQR)) 54 (40-64) 58 (47-63) 54 (38-64) 0.27 
Age at onset (median (IQR)) 51 (36-59) 53 (45-59) 51 (36-62) 0.26 
Sex       
Male 115 (68.5%) 26 (63.4%) 89 (70.1%) 0.44 
Comorbidities       
Diabetes mellitus 13 (7.7%) 5 (12.2%) 8 (6.3%) 0.31 
Psychiatric disorder 11 (6.5) 2 (4.9%) 9 (7.1%) 0.47 
Obesity 21 (12.5%) 2 (4.9%) 19 (15.0%) 0.11 
Osteoporosis 5 (3.0%) 5 (12.2%) 0 (0%) 0.35 
Hypothyroidism 3 (1.8%) 1 (2.4%) 2 (1.6%) 0.57 
Risk factors        
Smoking 63 (37.5%) 14 (34.1%) 49 (38.6%) 0.71 
NSAIDs 31 (18.5%) 5 (12.2%) 26 (20.5%) 0.26 
Soft drugs 6 (3.6%) 2 (4.9%) 4 (3.1%) 0.64 
Hard drugs 6 (3.6%) 2 (4.9%) 4 (3.1%) 0.64 
Alcohol abuse 7 (4.2%) 2 (4.9%) 5 (3.9%) 0.68 
ASA classification      0.40 
I 58 (35.5%) 14 (34.1%) 44 (39.3%)  
II 72 (42.9%) 20 (48.8%) 52 (46.4%)  
III 20 (11.9%) 4 (9.8%) 16 (14.3%)  
IV 1 (0.6%) 1 (2.4%) 0 (0.0%)  
Unknown 17 (10.1%) 2 (4.9%) 15 (11.8%)  
BMI, n = 150 (mean (SD)) 28,18 (5.38) 26.91 (4.68) 28,77 (5.54) 0.06 
 Unknown (n= ) 18 (10.7%) 1 (2.4%) 17 (13.4%)  
ISS       <0.001 
 <16 114 (67.9%) 16 (39.0%) 99 (78.0%)   
 >16 39 (23.2%) 18 (43.9%) 21 (16.5%)   
 Unknown 15 (8.9%) 7 (17.1%) 7 (5.5%)   
Fracture location    0.002 
Upper extremity 18 (10.7%) 1 (2.4%) 17 (13.4%)  
Lower extremity 140 (83.3%) 33 (80.5%) 107 (84.3%)  
Spine 7 (4.2%) 5 (12.2%) 2 (1.6%)  
Pelvis 3 (1.8%) 2 (4.9%) 1 (0.8%)  
Fracture type    0.85 
Open 80 (47,6%) 18 (43.9%) 62 (48.8%)  
Closed 79 (47.0%) 16 (39.0%) 63 (49.6%)  
Unknown 9 (5.4%) 7 (17.1%) 2 (1.6%)  
Gustilo-Anderson Classification (32)    0.04 
Grade 1 16 (9.5%) 3 (7.3%) 13 (10.2%)  
Grade 2 12 (7.1%) 0 (0.0%) 12 (9.4%)  
Grade 3 43 (19.7%) 11 (26.8%) 22 (17.4%)  
Unknown 19 (11.3%) 4 (9.8%) 15 (11.8%)  
 
Table 3. CRP, LC and ESR. 
  FRI       No FRI      
  TP TN Median  IQR FP FN Median  IQR 
CRP 49 36 15.0 mg/L 5.0-60.0 mg/L  69 10 7.0 mg/L 4.1-18.5 mg/L  
LC 22 72 9.3 x109/L 7.1-12.4 x109/L  26 35 8.1 x109/L 6.7-10.2 x109/L  
ESR 18 35 18.0 mm/h 7.0-36.0 mm/h  11 22 11.0 mm/h 5-31.5 mm/h  
 
Table 4. Diagnostic accuracies for CRP, LC and ESR. 
Test CRP LC ESR 
Sensitivity (95% CI) 83.1% (71.0%-91.6%) 38.6% (22.0%-52.4%) 45.0% (29.3% - 61.5%) 
Specificity (95% CI) 34.3% (25.3%-44.2%) 73.5% (63.6%-81.9%) 76.1% (61.2% - 87.4%) 
PPV (95% CI) 41.5% (37.2%-46.0%) 45.8% (34.7%-57.4%) 62.1% (46.8% - 75.2%) 
NPV (95% CI) 78.3% (65.9%-87.0%) 67.3% (61.9%-72.3%) 61.4% (53.5% - 68.7%) 
LR+ (95% CI) 1.26 (1.06-1.51) 1.45 (0.91-2.31) 1.88 (1.01 - 3.49) 
LR- (95% CI) 0.49 (0.26-0.92) 0.84 (0.66-1.06) 0.72 (0.52 - 1.00) 
Accuracy 51.8% (43.9%-59.7%) 60.7% (52.5%-68.4%) 79.6% (64.7% - 90.2%) 
 




Table 5. Diagnostic accuracies for continuous variables CRP, LC, ESR and CRP + LC. 
Test CRP LC ESR CRP + LC 
AUROC 0.64 (95% CI 0.55-0.72) 0.60 (95% CI 0.50-0.69) 0.58 (95% CI 0.46-0.71) 0.63 (95% CI 0.54-0.73) 
Sensitivity  61.0% 60.0% 72.4% 60.0%  
Specificity  62.9% 61.2% 50.1% 63.9% 
 
Table A. Models multivariable logistic regression analyses. 




DM ISS Smoking Lower extremity LC CRP 
1 0.63 0.54 - 0.73 152 -1.179 N/A N/A N/A N/A N/A N/A 0.005 0.048 
2  0.62 0.51 - 0.72 134 0.357 0.496 0.212 -0,158 -0.066 0.282 -0.811 N/A N/A 
3 0.66 0.55 - 0.77 123 -1.050 0.479 -0.101 0,804 -0.139 0.370 -0.746 0.044 0.007 
 
Multivariable logistic regression analysis 
ESR was left out of these analyses as this marker 
was missing in half of the patients (n=86, 51.2%). The 
AUROC of CRP and LC combined was 0.63 (95% CI 
0.54-0.73). At the Q-point, there were 33 TP, 62 TN, 35 
FP and 22 FN, with a sensitivity and specificity of 60% 
and 64% (Table 4 and Table 5). The model with 
clinical parameters and combined inflammatory 
markers had an AUROC of 0.66 (95% CI 0.55-0.77), as 
compared to 0.62 (95% CI 0.51-0.72) without 
inflammatory markers.  
 The AUROC of the combined markers per center 
was 0.63 (0.54-0.73) for the UMCG, and 0.68 (0.51-0.87) 
for the UMCU. The AUROC was 0.64 (0.34-0.93) <14 
days and 0.61 (0.48-0.75) ≥14 days. The AUROC of the 
model with log-transformed CRP and LC was 0.63 
(0.54-0.73). 
Discussion 
This study focused on the diagnostic accuracy of 
the serum inflammatory markers CRP, LC and ESR in 
patients who were suspected of FRI. It is the first 
study to include clinical parameters proven to be 
predictive of FRI in its analysis. Although most 
clinicians regard serum inflammatory markers to be 
part of the general work-up of suspected FRI, the 
results of this study indicate that they should be 
cautious when interpreting their results, as was 
published in the Consensus definition on FRI (2). 
The majority of the literature on inflammatory 
markers in orthopedic infection has focused on 
periprosthetic joint infections (PJI) and osteomyelitis 
of the diabetic foot (34-37). CRP has been proven to be 
useful in both (38, 39). Moreover, the value of LC is 
less well established. (9, 40) In early postoperative 
infections after fracture surgery, continuous elevation 
or a secondary rise might be expected in CRP and LC 
(24, 41). Levels of serum CRP, LC and ESR have been 
shown to be significantly lower in FRI than in 
hematogenous osteomyelitis and osteomyelitis of the 
diabetic foot (42, 43). 
Studies on the diagnostic value of serum 
inflammatory markers in FRI are limited, and their 
methodology is heterogeneous. Different serum 
marker thresholds are used, and study populations 
vary. As in the current study, the study population of 
Buhl et al. consisted of patients who underwent 
nuclear medical imaging for suspected FRI or infected 
prosthesis.(44) They reported a sensitivity and 
specificity for ESR of 84% and 29% respectively, and 
56% and 35% for CRP. These results differ from those 
in the current study. This may be due to PJI being 
excluded in the current study and the use of different 
thresholds. Most studies on serum markers in FRI 
have focused on subgroups of FRI, such as infected 
non-union or patients undergoing conversion 
surgery. One study reported on the value of CRP and 
ESR in diagnosing infection in patients undergoing 
conversion from internal fixation of a femoral neck 
fracture to total hip arthroplasty (45). The authors 
reported a higher diagnostic accuracy than the current 
study, with an AUROC of 0.89 for both markers. 
Unfortunately, their study has a high risk of 
overfitting due to the inclusion of only six patients 
with FRI. Therefore, the true AUROC, obtained after 
(internal and) external validation, will be much lower 
(46). Several studies have focused on the value of 
inflammatory markers in diagnosing infection in 
patients presenting with mal- or non-union (11-13). 
The diagnostic accuracy of individual serum 
inflammatory markers in this sub-group of FRI is low. 
Some of these studies have looked at the diagnostic 
accuracy of combined serum markers. Similar to the 
results of the current study, combining markers was 
found to increase the diagnostic accuracy for FRI only 
marginally.(11, 13)  
With an accuracy of 79.6%, the diagnostic value 
of ESR in the current study appears to be high. 
However, the large overlap in the IQR of the FRI and 
non-FRI groups shows the discriminative value of 
ESR to be low.  
The differences in results between the literature 
and the current study may be caused by several 
factors. Most importantly, several different thresholds 
are used to define elevation of serum inflammatory 
markers. This makes a valid comparison of results 
impossible, especially when only sensitivity and 




specificity are reported. Furthermore, FRI is a 
heterogeneous disease, with tissue involvement 
varying in location and severity. Some studies focus 
on all patients with FRI, others choose subgroups to 
increase population homogeneity. These differences 
in study populations further complicate comparing 
results and it is therefore imperative that international 
lab protocols are being developed and uniform 
diagnostic criteria including threshold values and 
timing for obtaining serum inflammatory markers 
regarding FRI are being established and 
implemented. Finally, most studies have looked at 
serum markers taken between 1 to 14 days prior to 
obtaining intra-operative cultures. The current study 
focused on inflammatory markers when infection was 
first suspected, with a median of 48.5 days between 
index- and reference test. This is in concordance with 
clinical practice, as the clinician will obtain serum 
inflammatory markers at the time an FRI has to be 
confirmed or ruled out. The actual surgery often 
follows at a later point, when additional diagnostic 
work, such as imaging, has been completed. This 
difference may have influenced the results.  
Strengths of this study are that it is one of the 
largest cohorts investigating the diagnostic 
performance of individual and combined serum 
inflammatory markers in FRI. The inclusion of 
combined markers is important, as in clinical practice, 
inflammatory markers are never interpreted 
individually. Furthermore, they are always 
interpreted in combination with clinical parameters. 
Therefore, information from multiple markers was 
combined with clinical parameters that are associated 
with FRI to estimate the probability of infection.  
This study does have some limitations. First of 
all, all patients with suspected FRI were collectively 
analyzed, and thus these results may not be 
applicable to all possible subgroups. Furthermore, 
due to its retrospective nature, there was no uniform 
time interval between index- and reference test. 
However, this is in accordance with clinical practice. 
In addition, the laboratory measurements have been 
performed using different methods, however due to 
laboratory standardization and internal and external 
quality control schemes differences due to 
measurement methods are negligible. Also, the 
outcome of this study might be affected by selection 
bias as the patients undergoing advanced nuclear 
imaging could have been selected based on the 
outcome of their serum inflammatory marker testing. 
This could potentially alter the true NPV of the 
markers.  
Conclusion 
The outcome of this retrospective study indicates 
that the added diagnostic value of CRP, LC and ESR 
seems to be limited for FRI. FRI can still be present 
when serum inflammatory markers are within normal 
range. Therefore, clinicians should be cautious when 
interpreting the results of these tests in patients with 
suspected FRI. 
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